Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acasti Pharma
(NQ:
ACST
)
2.460
-0.040 (-1.60%)
Streaming Delayed Price
Updated: 3:55 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
16,831
Open
2.420
Bid (Size)
2.360 (1)
Ask (Size)
2.540 (1)
Prev. Close
2.500
Today's Range
2.410 - 2.540
52wk Range
1.720 - 3.590
Shares Outstanding
44,612,831
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025
August 09, 2024
ACST stock results show that Acasti Pharma beat analyst estimates for earnings per share the first quarter of 2025.
Via
InvestorPlace
ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024
June 21, 2024
ACST stock results show that Acasti Pharma beat analyst estimates for earnings per share the fourth quarter of 2024.
Via
InvestorPlace
Performance
YTD
-10.87%
-10.87%
1 Month
-18.81%
-18.81%
3 Month
-8.55%
-8.55%
6 Month
-25.45%
-25.45%
1 Year
+14.42%
+14.42%
More News
Read More
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
June 18, 2024
Via
InvestorPlace
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
May 23, 2024
Via
InvestorPlace
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 26, 2023
Via
Benzinga
Recap: Acasti Pharma Q4 Earnings
June 23, 2023
Via
Benzinga
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 18, 2024
Via
Benzinga
Why Acasti Pharma (ACST) Stock Is Exploding Higher
September 26, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
May 09, 2023
Via
InvestorPlace
Acasti Pharma's Earnings Outlook
February 13, 2023
Via
Benzinga
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 05, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 22, 2023
Via
InvestorPlace
Acasti Pharma Reports Third Quarter 2023 Operational Results
February 14, 2023
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
January 25, 2023
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
January 24, 2023
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 14, 2023
February 14, 2023
Via
Benzinga
Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast
January 17, 2023
Via
Newsfile
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
January 13, 2023
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
January 06, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
January 06, 2023
Via
InvestorPlace
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
January 05, 2023
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
December 28, 2022
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
December 23, 2022
Via
Benzinga
Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket
December 23, 2022
Via
Benzinga
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
December 22, 2022
From
Acasti Pharma, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.